Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Stock Performance

NASDAQ:NBRV opened at $0.00 on Friday. The company has a market capitalization of $9,604.50, a P/E ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The stock’s fifty day simple moving average is $0.03.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.